Search results
Results from the WOW.Com Content Network
The Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 trial, also known as PROVE-IT TIMI 22, was a randomized, double-blind, clinical trial that recruited 4,162 people admitted within 10 days of an acute coronary event and randomised them to the lipid-lowering drugs pravastatin (40 mg) or atorvastatin (80 mg) and a 10-day course of the ...
The absolute risk reduction (ARR), however, was much smaller, because the study group did not have a very high rate of cardiovascular events over the study period: 2.67% in the control group, compared to 1.65% in the treatment group. [15] Taking atorvastatin for 3.3 years, therefore, would lead to an ARR of only 1.02% (2.67% minus 1.65%).
Elevations threefold greater than normal were recorded in 0.5% of people treated with atorvastatin 10 mg-80 mg rather than placebo. [70] Usage instructions in package inserts for this statin define the requirement that hepatic function be assessed with laboratory tests before beginning atorvastatin treatment and repeated periodically as ...
Atorvastatin 26 – 60 5 – 13 17 – 53 25 – 45 CYP3A4 98 13–30 No 8 Lovastatin 21 – 42 2 – 10 6 – 27 16 – 34 CYP3A4 >95 2 – 4 No NA Simvastatin 26 – 47 8 – 16 12 – 34 19 – 36 CYP3A4 95 – 98 1 – 3 No 11 Fluvastatin 22 – 36 3 – 11 12 – 25 16 – 27 CYP2C9 98 0,5 – 3,0 No 28 Rosuvastatin 45 – 63 8 – 14 10 ...
In a randomized study it showed a LDL-C reduction of 63.6 percent, significantly more than bempedoic acid/ezetimibe, and it may also be more effective than bempedoic acid / statin combination therapy.
Guidelines by the American College of Cardiology and the American Heart Association recommend statin treatment for primary prevention of cardiovascular disease in adults with LDL cholesterol ≥ 190 mg/dL (4.9 mmol/L) or those with diabetes, age 40–75 with LDL-C 70–190 mg/dL (1.8–4.9 mmol/dL); or in those with a 10-year risk of developing ...
Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug. In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet. [ 1 ]
The number needed to treat in the study was 57 to postpone one death and 19 to prevent one cardiovascular "event" (in those taking the drug simvastatin for 5 years). There was no mortality benefit in women with a statistical "p-value" that did not reach significance (0.08) while the Kaplan-Meier mortality curves, for men and women separately ...